ReviewFrontiers in immunology2026

Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies.

Luis Álvarez-Vallina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.